This segment focuses on the research, development, and commercialization of novel therapeutics for rare diseases. The primary focus is on Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS). Research and development activities include Phase III clinical trials, formulation development, and manufacturing process optimization. Technologies and methodologies include advanced drug delivery systems and clinical trial design. The therapeutic area is primarily focused on PWS, with the potential to expand to other rare genetic disorders. The patient impact is significant, as DCCR aims to address the unmet medical needs of individuals with PWS, improving their quality of life. Market positioning is centered on being a leader in PWS treatment, with a competitive advantage in its advanced clinical development program. Future opportunities include expanding the label for DCCR and developing new therapies for other rare diseases. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials. Partnerships and collaborations include a collaboration with Vanderbilt University to discover and develop next-generation K(ATP) channel activators for the treatment of rare diseases.